Global Retirement Partners LLC Reduces Stock Holdings in GSK plc (NYSE:GSK)

Global Retirement Partners LLC lowered its holdings in shares of GSK plc (NYSE:GSK) by 8.1% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 36,847 shares of the pharmaceutical company’s stock after selling 3,263 shares during the quarter. Global Retirement Partners LLC’s holdings in GSK were worth $1,246,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in GSK. Allspring Global Investments Holdings LLC increased its holdings in GSK by 40.7% during the third quarter. Allspring Global Investments Holdings LLC now owns 11,764 shares of the pharmaceutical company’s stock valued at $481,000 after buying an additional 3,405 shares during the last quarter. Foundations Investment Advisors LLC grew its position in shares of GSK by 4.8% during the 3rd quarter. Foundations Investment Advisors LLC now owns 10,122 shares of the pharmaceutical company’s stock valued at $414,000 after acquiring an additional 466 shares during the period. Sequoia Financial Advisors LLC increased its stake in shares of GSK by 2.6% in the 3rd quarter. Sequoia Financial Advisors LLC now owns 22,937 shares of the pharmaceutical company’s stock worth $938,000 after purchasing an additional 577 shares in the last quarter. Eastern Bank bought a new position in GSK in the 3rd quarter worth $26,000. Finally, International Assets Investment Management LLC lifted its position in GSK by 3,991.9% during the third quarter. International Assets Investment Management LLC now owns 226,487 shares of the pharmaceutical company’s stock valued at $92,590,000 after purchasing an additional 220,952 shares in the last quarter. Institutional investors own 15.74% of the company’s stock.

GSK Stock Performance

Shares of NYSE GSK opened at $36.62 on Friday. The company has a market cap of $75.91 billion, a P/E ratio of 23.03, a P/E/G ratio of 1.11 and a beta of 0.64. GSK plc has a 52-week low of $31.72 and a 52-week high of $45.92. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.52 and a current ratio of 0.78. The firm’s fifty day moving average is $34.61 and its two-hundred day moving average is $37.36.

GSK (NYSE:GSK) last issued its earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. As a group, analysts anticipate that GSK plc will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, April 10th. Stockholders of record on Friday, February 21st will be issued a dividend of $0.3932 per share. This represents a $1.57 annualized dividend and a dividend yield of 4.29%. This is a boost from GSK’s previous quarterly dividend of $0.39. The ex-dividend date is Friday, February 21st. GSK’s dividend payout ratio is 93.08%.

Analyst Upgrades and Downgrades

A number of analysts have commented on the company. Guggenheim cut GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. StockNews.com upgraded shares of GSK from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 7th. Morgan Stanley started coverage on shares of GSK in a research report on Wednesday, February 12th. They issued an “equal weight” rating for the company. Jefferies Financial Group cut shares of GSK from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $53.00 to $39.50 in a research note on Tuesday, November 12th. Finally, Deutsche Bank Aktiengesellschaft cut shares of GSK from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Seven investment analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $43.25.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.